Article

Inspire agrees to sell InSite anti-infective

Alameda, CA-Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.'s topical anti-infective for treating bacterial conjunctivitis (AzaSite).

Alameda, CA-Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.'s topical anti-infective for treating bacterial conjunctivitis (AzaSite).

The product combines a topical 1% azithromycin formulation with InSite's patented ophthalmic drug-delivery system (DuraSite), designed to increase ocular retention of the drug.

Under the agreement, InSite will grant Inspire exclusive rights to market the anti-infective in the United States and Canada. Inspire will make an initial $13 million payment to InSite, with an additional $19 million pending FDA grants regulatory approval. Inspire also will pay a 20% royalty on net sales for the first 2 years and 25% thereafter.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.